Objective: Ruptured endovascular aortic aneurysm repair (REVAR) is being increasingly used to treat ruptured abdominal aortic aneurysms (rAAAs). However, the comparison between totally percutaneous (pREVAR) vs femoral cutdown (cREVAR) access for REVAR has not been studied. We used a national surgical database to evaluate the 30-day outcomes in patients undergoing pREVAR vs cREVAR.
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Questions Society for Vascular Surgery Phone: 800-258-7188; education@vascularsociety.org cutdown, 64% had bilateral femoral cutdowns, and 10% had single femoral cutdown. Univariate analysis showed there were no significant differences in age, gender, body mass index, AAA size, or other high-risk physiologic comorbidities between the two groups. There was also no difference in rates of preoperative hemodynamic instability (48.1% vs 45.0%; P ¼ .55) or need for perioperative transfusion (67.4% vs 67.8%; P ¼ .94). There was a higher incidence of use of regional anesthesia for pREVAR compared with cREVAR (20.9% vs 7.8%; P < .01). The incidence of postoperative wound complications was similar between both groups (4.8% vs 5.4%; P ¼ .79), whereas hospital length of stay was shorter in the pREVAR group (mean difference, 1.3 days). Overall 30-day mortality was higher in the pREVAR group (28.7% vs 20.1%; P ¼ .04), and operative time was longer (mean difference, 6.3 minutes). However, when pREVARs done in 2011 to 2012 were compared with those done in 2013 to 2014, 30-day mortality decreased from 38.2% to 25.3% and operative time decreased by 25 minutes (188 to 163 minutes). Multivariate analysis showed there were no significant differences in mortality, wound complications, hospital length of stay, or operative time between pREVAR and cREVAR.
Conclusions:
The ACS NSQIP targeted vascular database shows that there has been increased adoption of pREVAR in recent years, with improved mortality and operative time over the 4-year study period. At this point, pREVAR has not yet been shown to be superior to cREVAR for rAAA, but these outcome improvements are encouraging and likely attributable to increased operator experience. (J Vasc Surg 2017;66:1364-70.)
A ruptured abdominal aortic aneurysm (rAAA) is a highly morbid event, with mortality rates historically >80%. An estimated >50% of patients with rAAA never reach a hospital facility alive. 1 Mortality after surgical repair varies, with most larger retrospective series reporting mortality rates ranging from 40% to 50%. 2, 3 Improved emergency medical services and critical care advances over the past several decades are thought to have improved this dismal prognosis.
In the current era of endovascular AAA repair (EVAR), percutaneous access to the femoral vessels has been increasingly used for elective EVARs. A multicenter randomized controlled trial with 151 patients at 20 institutions demonstrated that a totally percutaneous approach to elective EVAR (pEVAR) procedures had reached a success rate of >90%. This study further demonstrated a reduction in total procedure time with pEVAR and a trend toward decreased hospital length of stay compared with a femoral cutdown (cEVAR) approach. 4 Buck et al 5 reexamined this comparison of elective pEVARs with elective cEVAR in a large national database study. Their study demonstrated a mean 17-minute shorter operative time and shorter mean hospital length of stay with fewer postoperative wound complications in the pEVAR group. 5 The first EVAR for a rAAA (REVAR) was reported by Marin and Veith 6 in 1994. Since then, EVAR to treat rAAAs has expanded, contributing to improved survival among those able to reach a facility where they can undergo definitive repair. 7, 8 To date, no studies have compared pREVAR vs cREVAR for EVAR of rAAA. In this study, we used a national database to identify trends in the use of pREVAR for repair of rAAA and analyze outcome differences between the two access methods.
METHODS
Data source. We performed a retrospective review of the American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) Targeted Endovascular Abdominal Aortic Aneurysm Repair ("EVAR") database encompassing all EVAR procedures performed at participating hospitals from January 1, 2011, to December 31, 2014, inclusively. There were 71 centers that participated in the targeted EVAR data set in 2011, and this rose to 75 centers participating in 2014. The ACS-NSQIP is a nationally validated, risk-adjusted, outcomes-based program to measure and improve the quality of surgical care in the United States. The first year that the procedure-targeted data were collected in NSQIP was 2011. This targeted database prospectively collects procedure-specific demographics, anatomic details, perioperative details, and 30-day postoperative outcomes data specific to those undergoing EVAR. The deidentified targeted database was merged with the same cases in the general participant use file by case ID, allowing for both procedure-specific and general perioperative variables and outcomes collected in NSQIP to be analyzed.
Data from NSQIP are available to those institutions actively reporting data and enrolled in the program. The data in both the general and procedurally targeted databases are collected and entered by surgical clinical reviewers who are certified by the ACS. Strict variable definitions are used when data are collected to ensure consistency across participating centers, and periodic auditing is used to ensure accuracy. 9 Analysis of the NSQIP database is exempt from requiring informed consent from individual patients, and therefore, this study did not require Institutional Review Board approval. No center or provider-specific data are thus available for patient privacy purposes.
Study cohort and variables. Patients who underwent EVAR between 2011 and 2014, inclusively, were identified from the NSQIP targeted database. Within the "EVAR" database, the indication for aneurysm repair included the following options: "diameter," "dissection," "embolization," "nonruptured symptomatic," "other," "prior endovascular intervention with unsatisfactory result," "thrombosis,"
"rupture with hypotension or use of pressors," and "rupture without hypotension." Our study cohort included all patients in whom the indication was entered as "rupture with hypotension or use of pressors" or "rupture without hypotension." This study group was then broken down by type of access. The pREVAR group was defined as bilateral percutaneous access (whether successful or converted to open cutdown), and the cREVAR group was defined as planned unilateral or bilateral femoral artery cutdown access.
Preoperative variables analyzed included age, demographics, and comorbid conditions, including active smoking, diabetes, congestive heart failure, hypertension requiring medication, end-stage renal disease requiring dialysis, obesity, and preoperative functional independence. Anatomic variables analyzed included aneurysm size, proximal aneurysm extent, and distal aneurysm extent. Perioperative details compared included type of anesthesia used (general anesthesia, spinal/epidural, or regional anesthesia), bleeding requiring intraoperative or postoperative transfusion, and need for concomitant procedures. Concomitant procedures were specifically identified and included renal stenting, hypogastric embolization, lower extremity revascularization, and use of iliac branched device, aortic bare-metal stent, or iliac bare-metal stent.
Primary outcomes analyzed were mortality #30 days, hospital length of stay, operative time, and incidence of wound complications. Secondary outcomes included other surgical and medical postoperative complications and discharge destination.
Statistical analysis. Trends of pREVAR use during the study period were evaluated. Univariate and multivariate analyses were then performed to compare the demographic makeup, anatomic details, and outcomes of patients undergoing pREVAR vs cREVAR. Categoric variables were compared by the c 2 test, and continuous variables were compared by the Student t-test or the Mann-Whitney U test where appropriate. A priori adjustments for age, gender, race, comorbid conditions, type of anesthesia, bleeding requiring transfusion, hypotensive status, aneurysm size, type of main-body device, and proximal and distal aneurysm extent were entered into a multivariable logistic regression model to estimate adjusted odds ratios with 95% confidence intervals for mortality and wound complications. A linear regression model was used to identify the mean differences in hospital length of stay and operative time. We subsequently performed subgroup analysis comparing the first 2 years of the study period (2011-2012) to outcomes in the final 2 years of the study period (2013-2014). Univariate and multivariate analyses were performed for these comparisons as well. Statistical significance was defined as P < .05. All statistical analysis was performed with SAS 9.4 software (SAS Institute, Inc, Cary, NC).
RESULTS
Between January 1, 2011, and December 31, 2014, inclusively, 502 patients (78.5% men) were identified who underwent EVAR of a rAAA in the ACS-NSQIP targeted "EVAR" database. Mean age was 74.6 years. Among this study cohort, 129 patients had pREVAR (25.7%) and 373 had cREVAR (74.3%). Use of pREVAR for repair of rAAAs rose steadily over the study period, starting at 14.0% in 2011 and reaching 32.5% in 2014 (Fig) . Of all patients undergoing REVAR, 24% had bilateral percutaneous access, 2% had attempted percutaneous access converted to cutdown, 64% had bilateral femoral cutdowns, and 10% had a unilateral femoral cutdown. When univariate analysis was used to compare the pREVAR group with the cREVAR group, there were no statistically significant differences in patient age, frequency of male gender, body mass index, or any of the comorbid conditions evaluated, including obesity, active smoking, diabetes, congestive heart failure, hypertension requiring medication, preoperative end-stage renal disease requiring dialysis, and functional independence (Table I) . Although most of both populations in this cohort were of white race, there was a statistically significantly higher percentage of white race in the cREVAR group (80.7% vs 71.3%; P ¼ .03).
With regard to perioperative and anatomic characteristics, aneurysm size did not differ significantly between the two groups. The most common range of aneurysm size was between 7 and 7.9 cm in both groups. Furthermore, there were no differences in the proximal or distal extent of the aneurysm, with most occurring in the infrarenal location in both groups (84% vs 80%).
Preoperative hemodynamic instability did not differ significantly between pREVAR and cREVAR (48.1% vs 
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45.0%; P ¼ .55) nor did the need for perioperative transfusion (67.4% vs 67.8%; P ¼ .94). There was a higher rate of regional anesthesia vs general anesthesia in the pREVAR group (20.9% vs 7.8%; P < .01). The use of concomitant procedures was slightly higher the cREVAR group, but this was not statistically significant (35.1% vs 28.6%; P ¼ .18). Conversion to open aneurysm repair was higher in pREVAR group compared with cREVAR (6.2% vs 2.1%; P ¼ .02) (Table II) . Among the eight conversions in each group, there were five deaths in each of the pREVAR and cREVAR groups, leading to a mortality rate of 62.5% with those requiring a conversion to open aneurysm repair.
Overall 30-day mortality was higher in the pREVAR group (28.7% vs 20.1%; P ¼ .04). The mean operative time was just slightly longer for pREVAR, although not statistically significant (169.6 vs 163.2 minutes; P ¼ .58). The incidence of wound complications was similar between the groups (4.8% vs 5.4%; P ¼ .79), whereas hospital length of stay was decreased in the pREVAR group (mean difference, 1.3 days) (Table III) . Additional outcomes are outlined in Table IV . Among the 10 patients whose attempted percutaneous access was converted to open femoral cutdown, two ultimately required conversion to an open aneurysm repair. Mean operative time was 220.5 minutes (range, 62-574 minutes), and four ultimately died #30 days.
After adjusting for differences in age, gender, hypotensive status, need for perioperative transfusion, anesthesia type, need for concomitant procedure, and aneurysm characteristics, no significant differences were found between pREVAR and cREVAR in 30-day mortality, rates of wound complications, operative time, or hospital length of stay (Table V) . On subgroup analysis comparing those procedures performed in 2011 to 2012 with those performed in 2013 to 2014, 30-day mortality decreased in the pREVAR group from 38.2% to 25.3%. Operative times similarly decreased by 25 minutes, from 188 to 163 minutes. There was, however, still no significant difference for any of the primary outcomes when pREVAR was compared with cREVAR in the most recent 2-year cohort (Table III) .
DISCUSSION
In this study, we demonstrated that in the national ACS-NSQIP targeted vascular database, pREVAR has been increasingly used in recent years, reaching 32% in 2014 among participating hospitals. In just over 500 REVAR procedures tallied over 4 years, overall mortality #30 days in this study cohort was 22.3%. After adjustment for age, gender, hypotensive status, anesthesia type, need for concomitant procedures, need for transfusion, and aneurysm characteristics, we ultimately did not find statistically significant differences in mortality, operative time, rate of wound complications, or hospital length of stay between the two groups. However, primary outcomes, including mortality, improved over the 4-year study period. When broken down by access type, mean operative time decreased much more dramatically in the pREVAR group (24 minutes) than the cREVAR group (5 minutes). The improvement in 30-day mortality was also much more dramatic in the pREVAR group when the first 2 years of the study were compared with the latter 2 years (12.9% vs 3.1%). The significant disparity in unadjusted mortality noted in the first 2 years between pREVAR and cREVAR disappeared when the more recent data were compared.
The adoption of more minimally invasive strategies has been the natural evolution of surgical care with advances in technology. This has led to improved recovery profiles and decreased physiologic derangement associated with maximally invasive surgery. This has logically led to the application of this paradigm to rAAAs. This technologic advancement has been highlighting the enhanced ability to perform their procedure under regional anesthesia. The benefits of shorter operative time and decreased wound complications seen in the elective setting for elective pEVAR do not appear to be applicable at this point to the rupture setting. Despite patients in the cREVAR group requiring more concomitant procedures, operative time still remained longer in the pREVAR group. This may be due to a multitude of factors, not only access technique; however, it is likely that over the study period, familiarity with percutaneous closure devices and the percutaneous technique may have played a role in longer operative times earlier in the study. The trends of decreasing operative time for pREVAR are encouraging, however, as is the potential for earlier discharge from the hospital among those patients who survive.
On initial comparison, the worse mortality in the pREVAR group over the cREVAR group was surprising. However, after adjustment for demographic, anatomic details, hemodynamic stability, anesthetic type, and operative details, no statistical significant difference was seen between the two groups. Although rates of presentation with hypotension and need for perioperative transfusion were similar between the two groups, our hypothesis is that patients in the pREVAR group were disproportionately sicker. This may be explained by the significantly higher percentage of pREVAR procedures done under regional anesthesia (20.9% vs 7.8%). Regional anesthesia was defined as monitored anesthesia care, intravenous sedation and local anesthesia, and excluded use of general, spinal, or epidural anesthesia. However, admittedly, without more granularity in hospital records, it is impossible to tell whether more procedures were done under regional anesthesia because of the planned percutaneous access or whether percutaneous access was chosen because of the treating physicians' aversion to general anesthesia in the most critically ill patients. That wound complications did not differ between the pREVAR and cREVAR groups on univariate or multivariate analysis was particularly surprising. It is possible that the associated learning curves associated with the advent of the various percutaneous closure devices and techniques gaining increased usage accounted for increases in complications such as hematomas and pseudoaneurysms. Those may have accounted for wound complications in the early years of the study while wound infections associated with groin cutdowns remained constant. However, the type of local wound complications could, unfortunately, not be parsed in this database. Importantly, rates of these complications have decreased in recent years, likely owing to improved operator experience. The slightly higher rate of conversion to open procedures in the pREVAR group was also surprising. The low numbers, however, preclude any robust analysis for variances in risk factors for conversion. Our study has a number of limitations, starting with its retrospective nature, potential selection bias, and lack of center-specific or provider-specific data. Because rupture of an AAA is an acute, emergency problem, a sense of how critically ill patients are at presentation is of great importance. We examined need for perioperative transfusion and documentation of rupture with hypotension or requirement of pressor support as markers for patients in extremis. However, it is possible there were other variables not included in the database that could be contributing to differences in outcomes. Specifically, we could not tell whether active permissive hypotension was used. Whereas in the elective setting, comorbidities and functional status may impart indication of frailty, this is less important in the ruptured setting and thus was examined but not included in the multivariate regression model. An additional limitation is in the lack of an indication of severity of certain outcome measures, such as wound complications, which can vary from wound healing disorders that can be treated conservatively to large pseudoaneurysms that require further intervention. This study was able to use a large nationwide data set of real-world practice to examine a rapidly advancing field with patient numbers likely not accruable in a single-institution study nor replicable in a randomized controlled trial.
CONCLUSIONS
This study shows increased use of percutaneous access to treat rAAAs endovascularly with noninferiority to the traditional femoral cutdown approach. We have shown improvement in outcomes overall and particularly among those undergoing pREVAR in recent years. We believe these improved outcomes are attributable to increases in user experience and comfort level with percutaneous access. Such trends in outcomes of pREVAR are encouraging because totally percutaneous access for REVAR appears to be a viable first option for access. 
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